nodes	percent_of_prediction	percent_of_DWPC	metapath
Propafenone—CYP3A4—bone cancer	0.677	1	CbGaD
Propafenone—CYP2C9—Cisplatin—bone cancer	0.00767	0.235	CbGbCtD
Propafenone—ABCB1—Cisplatin—bone cancer	0.00745	0.228	CbGbCtD
Propafenone—ABCB1—Doxorubicin—bone cancer	0.00499	0.153	CbGbCtD
Propafenone—ABCB1—Methotrexate—bone cancer	0.00483	0.148	CbGbCtD
Propafenone—CYP2D6—Doxorubicin—bone cancer	0.0047	0.144	CbGbCtD
Propafenone—KCNH2—Hematopoietic Stem Cell Differentiation—FLI1—bone cancer	0.00359	0.0686	CbGpPWpGaD
Propafenone—SCN5A—Cardiac Progenitor Differentiation—T—bone cancer	0.00332	0.0634	CbGpPWpGaD
Propafenone—CYP3A4—Doxorubicin—bone cancer	0.00299	0.0916	CbGbCtD
Propafenone—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.0028	0.0536	CbGpPWpGaD
Propafenone—SCN5A—SIDS Susceptibility Pathways—FEV—bone cancer	0.00165	0.0315	CbGpPWpGaD
Propafenone—KCNH2—SIDS Susceptibility Pathways—FEV—bone cancer	0.0016	0.0305	CbGpPWpGaD
Propafenone—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00132	0.0253	CbGpPWpGaD
Propafenone—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00127	0.0242	CbGpPWpGaD
Propafenone—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00116	0.0221	CbGpPWpGaD
Propafenone—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00109	0.0209	CbGpPWpGaD
Propafenone—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00109	0.0208	CbGpPWpGaD
Propafenone—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00109	0.0207	CbGpPWpGaD
Propafenone—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.00108	0.0207	CbGpPWpGaD
Propafenone—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00108	0.0206	CbGpPWpGaD
Propafenone—Mirabegron—CYP3A4—bone cancer	0.00107	0.174	CrCbGaD
Propafenone—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00103	0.0197	CbGpPWpGaD
Propafenone—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.00103	0.0197	CbGpPWpGaD
Propafenone—Salmeterol—CYP3A4—bone cancer	0.000979	0.16	CrCbGaD
Propafenone—KCNH2—Hematopoietic Stem Cell Differentiation—IL3—bone cancer	0.000938	0.0179	CbGpPWpGaD
Propafenone—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000921	0.0176	CbGpPWpGaD
Propafenone—Oxaprozin—PTGS2—bone cancer	0.000758	0.123	CrCbGaD
Propafenone—Salsalate—PTGS2—bone cancer	0.000758	0.123	CrCbGaD
Propafenone—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000711	0.0136	CbGpPWpGaD
Propafenone—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000669	0.0128	CbGpPWpGaD
Propafenone—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000639	0.0122	CbGpPWpGaD
Propafenone—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000634	0.0121	CbGpPWpGaD
Propafenone—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000627	0.012	CbGpPWpGaD
Propafenone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000623	0.0119	CbGpPWpGaD
Propafenone—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.000615	0.0117	CbGpPWpGaD
Propafenone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000582	0.0111	CbGpPWpGaD
Propafenone—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.00057	0.0109	CbGpPWpGaD
Propafenone—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000531	0.0101	CbGpPWpGaD
Propafenone—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000525	0.01	CbGpPWpGaD
Propafenone—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.00052	0.00993	CbGpPWpGaD
Propafenone—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000505	0.00964	CbGpPWpGaD
Propafenone—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.0005	0.00955	CbGpPWpGaD
Propafenone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000498	0.0095	CbGpPWpGaD
Propafenone—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000484	0.00924	CbGpPWpGaD
Propafenone—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000468	0.00894	CbGpPWpGaD
Propafenone—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000464	0.00886	CbGpPWpGaD
Propafenone—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000463	0.00884	CbGpPWpGaD
Propafenone—SCN5A—Cardiac Progenitor Differentiation—KIT—bone cancer	0.000451	0.00861	CbGpPWpGaD
Propafenone—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000444	0.00849	CbGpPWpGaD
Propafenone—Carvedilol—CYP3A4—bone cancer	0.000431	0.0702	CrCbGaD
Propafenone—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000427	0.00816	CbGpPWpGaD
Propafenone—ADRB1—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.000424	0.0081	CbGpPWpGaD
Propafenone—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000396	0.00757	CbGpPWpGaD
Propafenone—Dextropropoxyphene—CYP3A4—bone cancer	0.000396	0.0646	CrCbGaD
Propafenone—Fentanyl—CYP3A4—bone cancer	0.000392	0.0639	CrCbGaD
Propafenone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000384	0.00733	CbGpPWpGaD
Propafenone—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000382	0.0073	CbGpPWpGaD
Propafenone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000364	0.00696	CbGpPWpGaD
Propafenone—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000357	0.00682	CbGpPWpGaD
Propafenone—Benzphetamine—CYP3A4—bone cancer	0.000347	0.0566	CrCbGaD
Propafenone—Atomoxetine—CYP3A4—bone cancer	0.000345	0.0562	CrCbGaD
Propafenone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00034	0.0065	CbGpPWpGaD
Propafenone—Phenoxybenzamine—CYP3A4—bone cancer	0.000332	0.0541	CrCbGaD
Propafenone—Propranolol—CYP3A4—bone cancer	0.000327	0.0534	CrCbGaD
Propafenone—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000306	0.00584	CbGpPWpGaD
Propafenone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000291	0.00555	CbGpPWpGaD
Propafenone—Hepatitis—Methotrexate—bone cancer	0.00027	0.00117	CcSEcCtD
Propafenone—Pollakiuria—Doxorubicin—bone cancer	0.00027	0.00117	CcSEcCtD
Propafenone—Haematuria—Epirubicin—bone cancer	0.000269	0.00116	CcSEcCtD
Propafenone—Urinary tract disorder—Methotrexate—bone cancer	0.000267	0.00115	CcSEcCtD
Propafenone—Hepatobiliary disease—Epirubicin—bone cancer	0.000267	0.00115	CcSEcCtD
Propafenone—Weight increased—Doxorubicin—bone cancer	0.000266	0.00115	CcSEcCtD
Propafenone—Epistaxis—Epirubicin—bone cancer	0.000266	0.00115	CcSEcCtD
Propafenone—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000265	0.00507	CbGpPWpGaD
Propafenone—Urethral disorder—Methotrexate—bone cancer	0.000265	0.00115	CcSEcCtD
Propafenone—Weight decreased—Doxorubicin—bone cancer	0.000265	0.00114	CcSEcCtD
Propafenone—Hyperglycaemia—Doxorubicin—bone cancer	0.000264	0.00114	CcSEcCtD
Propafenone—Agranulocytosis—Epirubicin—bone cancer	0.000263	0.00114	CcSEcCtD
Propafenone—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000262	0.005	CbGpPWpGaD
Propafenone—Infestation NOS—Doxorubicin—bone cancer	0.000261	0.00113	CcSEcCtD
Propafenone—Drowsiness—Doxorubicin—bone cancer	0.000261	0.00113	CcSEcCtD
Propafenone—Infestation—Doxorubicin—bone cancer	0.000261	0.00113	CcSEcCtD
Propafenone—Visual impairment—Methotrexate—bone cancer	0.000261	0.00113	CcSEcCtD
Propafenone—Hypersensitivity—Cisplatin—bone cancer	0.000258	0.00111	CcSEcCtD
Propafenone—Bradycardia—Epirubicin—bone cancer	0.000258	0.00111	CcSEcCtD
Propafenone—Renal failure—Doxorubicin—bone cancer	0.000256	0.00111	CcSEcCtD
Propafenone—Neuropathy peripheral—Doxorubicin—bone cancer	0.000256	0.00111	CcSEcCtD
Propafenone—Haemoglobin—Epirubicin—bone cancer	0.000254	0.0011	CcSEcCtD
Propafenone—Stomatitis—Doxorubicin—bone cancer	0.000254	0.0011	CcSEcCtD
Propafenone—Jaundice—Doxorubicin—bone cancer	0.000254	0.0011	CcSEcCtD
Propafenone—Rhinitis—Epirubicin—bone cancer	0.000254	0.0011	CcSEcCtD
Propafenone—Haemorrhage—Epirubicin—bone cancer	0.000253	0.00109	CcSEcCtD
Propafenone—Hepatitis—Epirubicin—bone cancer	0.000253	0.00109	CcSEcCtD
Propafenone—Eye disorder—Methotrexate—bone cancer	0.000253	0.00109	CcSEcCtD
Propafenone—Tinnitus—Methotrexate—bone cancer	0.000252	0.00109	CcSEcCtD
Propafenone—Hypoaesthesia—Epirubicin—bone cancer	0.000252	0.00109	CcSEcCtD
Propafenone—Asthenia—Cisplatin—bone cancer	0.000251	0.00109	CcSEcCtD
Propafenone—Cardiac disorder—Methotrexate—bone cancer	0.000251	0.00108	CcSEcCtD
Propafenone—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000251	0.00479	CbGpPWpGaD
Propafenone—Urinary tract disorder—Epirubicin—bone cancer	0.00025	0.00108	CcSEcCtD
Propafenone—Haematuria—Doxorubicin—bone cancer	0.000249	0.00107	CcSEcCtD
Propafenone—Connective tissue disorder—Epirubicin—bone cancer	0.000249	0.00107	CcSEcCtD
Propafenone—Urethral disorder—Epirubicin—bone cancer	0.000248	0.00107	CcSEcCtD
Propafenone—Hepatobiliary disease—Doxorubicin—bone cancer	0.000247	0.00107	CcSEcCtD
Propafenone—Epistaxis—Doxorubicin—bone cancer	0.000246	0.00106	CcSEcCtD
Propafenone—Angiopathy—Methotrexate—bone cancer	0.000245	0.00106	CcSEcCtD
Propafenone—Immune system disorder—Methotrexate—bone cancer	0.000244	0.00106	CcSEcCtD
Propafenone—Visual impairment—Epirubicin—bone cancer	0.000244	0.00105	CcSEcCtD
Propafenone—Mediastinal disorder—Methotrexate—bone cancer	0.000244	0.00105	CcSEcCtD
Propafenone—Agranulocytosis—Doxorubicin—bone cancer	0.000243	0.00105	CcSEcCtD
Propafenone—Diarrhoea—Cisplatin—bone cancer	0.00024	0.00104	CcSEcCtD
Propafenone—Alopecia—Methotrexate—bone cancer	0.000239	0.00103	CcSEcCtD
Propafenone—Bradycardia—Doxorubicin—bone cancer	0.000238	0.00103	CcSEcCtD
Propafenone—Mental disorder—Methotrexate—bone cancer	0.000237	0.00102	CcSEcCtD
Propafenone—ADRB1—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.000237	0.00453	CbGpPWpGaD
Propafenone—Eye disorder—Epirubicin—bone cancer	0.000237	0.00102	CcSEcCtD
Propafenone—Tinnitus—Epirubicin—bone cancer	0.000236	0.00102	CcSEcCtD
Propafenone—Malnutrition—Methotrexate—bone cancer	0.000235	0.00102	CcSEcCtD
Propafenone—Erythema—Methotrexate—bone cancer	0.000235	0.00102	CcSEcCtD
Propafenone—Haemoglobin—Doxorubicin—bone cancer	0.000235	0.00102	CcSEcCtD
Propafenone—Flushing—Epirubicin—bone cancer	0.000235	0.00102	CcSEcCtD
Propafenone—Cardiac disorder—Epirubicin—bone cancer	0.000235	0.00102	CcSEcCtD
Propafenone—Rhinitis—Doxorubicin—bone cancer	0.000235	0.00101	CcSEcCtD
Propafenone—Haemorrhage—Doxorubicin—bone cancer	0.000234	0.00101	CcSEcCtD
Propafenone—Hepatitis—Doxorubicin—bone cancer	0.000234	0.00101	CcSEcCtD
Propafenone—Hypoaesthesia—Doxorubicin—bone cancer	0.000233	0.00101	CcSEcCtD
Propafenone—Urinary tract disorder—Doxorubicin—bone cancer	0.000231	0.000999	CcSEcCtD
Propafenone—Dysgeusia—Methotrexate—bone cancer	0.000231	0.000996	CcSEcCtD
Propafenone—Connective tissue disorder—Doxorubicin—bone cancer	0.00023	0.000995	CcSEcCtD
Propafenone—Angiopathy—Epirubicin—bone cancer	0.00023	0.000992	CcSEcCtD
Propafenone—Urethral disorder—Doxorubicin—bone cancer	0.00023	0.000992	CcSEcCtD
Propafenone—Immune system disorder—Epirubicin—bone cancer	0.000229	0.000988	CcSEcCtD
Propafenone—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000228	0.00436	CbGpPWpGaD
Propafenone—Mediastinal disorder—Epirubicin—bone cancer	0.000228	0.000986	CcSEcCtD
Propafenone—Arrhythmia—Epirubicin—bone cancer	0.000226	0.000977	CcSEcCtD
Propafenone—Visual impairment—Doxorubicin—bone cancer	0.000226	0.000975	CcSEcCtD
Propafenone—Alopecia—Epirubicin—bone cancer	0.000224	0.000967	CcSEcCtD
Propafenone—Vomiting—Cisplatin—bone cancer	0.000223	0.000962	CcSEcCtD
Propafenone—Vision blurred—Methotrexate—bone cancer	0.000222	0.000959	CcSEcCtD
Propafenone—Mental disorder—Epirubicin—bone cancer	0.000222	0.000958	CcSEcCtD
Propafenone—Rash—Cisplatin—bone cancer	0.000221	0.000954	CcSEcCtD
Propafenone—Dermatitis—Cisplatin—bone cancer	0.000221	0.000953	CcSEcCtD
Propafenone—Erythema—Epirubicin—bone cancer	0.00022	0.000952	CcSEcCtD
Propafenone—Malnutrition—Epirubicin—bone cancer	0.00022	0.000952	CcSEcCtD
Propafenone—Eye disorder—Doxorubicin—bone cancer	0.000219	0.000946	CcSEcCtD
Propafenone—Ill-defined disorder—Methotrexate—bone cancer	0.000218	0.000944	CcSEcCtD
Propafenone—Tinnitus—Doxorubicin—bone cancer	0.000218	0.000944	CcSEcCtD
Propafenone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000218	0.00416	CbGpPWpGaD
Propafenone—Anaemia—Methotrexate—bone cancer	0.000218	0.00094	CcSEcCtD
Propafenone—Cardiac disorder—Doxorubicin—bone cancer	0.000217	0.000939	CcSEcCtD
Propafenone—Flushing—Doxorubicin—bone cancer	0.000217	0.000939	CcSEcCtD
Propafenone—Flatulence—Epirubicin—bone cancer	0.000217	0.000938	CcSEcCtD
Propafenone—Tension—Epirubicin—bone cancer	0.000216	0.000934	CcSEcCtD
Propafenone—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000216	0.00412	CbGpPWpGaD
Propafenone—Dysgeusia—Epirubicin—bone cancer	0.000216	0.000932	CcSEcCtD
Propafenone—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000215	0.00411	CbGpPWpGaD
Propafenone—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000215	0.00411	CbGpPWpGaD
Propafenone—Nervousness—Epirubicin—bone cancer	0.000214	0.000925	CcSEcCtD
Propafenone—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000213	0.00407	CbGpPWpGaD
Propafenone—Angiopathy—Doxorubicin—bone cancer	0.000212	0.000918	CcSEcCtD
Propafenone—Malaise—Methotrexate—bone cancer	0.000212	0.000918	CcSEcCtD
Propafenone—Muscle spasms—Epirubicin—bone cancer	0.000212	0.000915	CcSEcCtD
Propafenone—Immune system disorder—Doxorubicin—bone cancer	0.000212	0.000914	CcSEcCtD
Propafenone—Vertigo—Methotrexate—bone cancer	0.000212	0.000914	CcSEcCtD
Propafenone—Mediastinal disorder—Doxorubicin—bone cancer	0.000211	0.000912	CcSEcCtD
Propafenone—Leukopenia—Methotrexate—bone cancer	0.000211	0.000911	CcSEcCtD
Propafenone—Arrhythmia—Doxorubicin—bone cancer	0.000209	0.000904	CcSEcCtD
Propafenone—Nausea—Cisplatin—bone cancer	0.000208	0.000899	CcSEcCtD
Propafenone—Vision blurred—Epirubicin—bone cancer	0.000208	0.000897	CcSEcCtD
Propafenone—Alopecia—Doxorubicin—bone cancer	0.000207	0.000894	CcSEcCtD
Propafenone—Cough—Methotrexate—bone cancer	0.000205	0.000888	CcSEcCtD
Propafenone—Mental disorder—Doxorubicin—bone cancer	0.000205	0.000887	CcSEcCtD
Propafenone—Ill-defined disorder—Epirubicin—bone cancer	0.000204	0.000883	CcSEcCtD
Propafenone—Convulsion—Methotrexate—bone cancer	0.000204	0.000882	CcSEcCtD
Propafenone—Erythema—Doxorubicin—bone cancer	0.000204	0.000881	CcSEcCtD
Propafenone—Malnutrition—Doxorubicin—bone cancer	0.000204	0.000881	CcSEcCtD
Propafenone—Anaemia—Epirubicin—bone cancer	0.000204	0.00088	CcSEcCtD
Propafenone—Flatulence—Doxorubicin—bone cancer	0.000201	0.000868	CcSEcCtD
Propafenone—Myalgia—Methotrexate—bone cancer	0.0002	0.000866	CcSEcCtD
Propafenone—Chest pain—Methotrexate—bone cancer	0.0002	0.000866	CcSEcCtD
Propafenone—Tension—Doxorubicin—bone cancer	0.0002	0.000865	CcSEcCtD
Propafenone—Dysgeusia—Doxorubicin—bone cancer	0.0002	0.000863	CcSEcCtD
Propafenone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000199	0.00086	CcSEcCtD
Propafenone—Malaise—Epirubicin—bone cancer	0.000199	0.000859	CcSEcCtD
Propafenone—Discomfort—Methotrexate—bone cancer	0.000198	0.000856	CcSEcCtD
Propafenone—Nervousness—Doxorubicin—bone cancer	0.000198	0.000856	CcSEcCtD
Propafenone—Vertigo—Epirubicin—bone cancer	0.000198	0.000855	CcSEcCtD
Propafenone—Syncope—Epirubicin—bone cancer	0.000198	0.000854	CcSEcCtD
Propafenone—Leukopenia—Epirubicin—bone cancer	0.000197	0.000852	CcSEcCtD
Propafenone—Muscle spasms—Doxorubicin—bone cancer	0.000196	0.000847	CcSEcCtD
Propafenone—Palpitations—Epirubicin—bone cancer	0.000195	0.000841	CcSEcCtD
Propafenone—Confusional state—Methotrexate—bone cancer	0.000194	0.000837	CcSEcCtD
Propafenone—Loss of consciousness—Epirubicin—bone cancer	0.000194	0.000837	CcSEcCtD
Propafenone—Cough—Epirubicin—bone cancer	0.000192	0.000831	CcSEcCtD
Propafenone—Vision blurred—Doxorubicin—bone cancer	0.000192	0.00083	CcSEcCtD
Propafenone—Convulsion—Epirubicin—bone cancer	0.000191	0.000825	CcSEcCtD
Propafenone—Infection—Methotrexate—bone cancer	0.000191	0.000825	CcSEcCtD
Propafenone—Hypertension—Epirubicin—bone cancer	0.00019	0.000822	CcSEcCtD
Propafenone—Ill-defined disorder—Doxorubicin—bone cancer	0.000189	0.000817	CcSEcCtD
Propafenone—Nervous system disorder—Methotrexate—bone cancer	0.000188	0.000814	CcSEcCtD
Propafenone—Anaemia—Doxorubicin—bone cancer	0.000188	0.000814	CcSEcCtD
Propafenone—Thrombocytopenia—Methotrexate—bone cancer	0.000188	0.000813	CcSEcCtD
Propafenone—Myalgia—Epirubicin—bone cancer	0.000188	0.000811	CcSEcCtD
Propafenone—Chest pain—Epirubicin—bone cancer	0.000188	0.000811	CcSEcCtD
Propafenone—Anxiety—Epirubicin—bone cancer	0.000187	0.000808	CcSEcCtD
Propafenone—Skin disorder—Methotrexate—bone cancer	0.000187	0.000807	CcSEcCtD
Propafenone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000186	0.000805	CcSEcCtD
Propafenone—Hyperhidrosis—Methotrexate—bone cancer	0.000186	0.000803	CcSEcCtD
Propafenone—Discomfort—Epirubicin—bone cancer	0.000185	0.000801	CcSEcCtD
Propafenone—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000185	0.00352	CbGpPWpGaD
Propafenone—Malaise—Doxorubicin—bone cancer	0.000184	0.000794	CcSEcCtD
Propafenone—Dry mouth—Epirubicin—bone cancer	0.000183	0.000793	CcSEcCtD
Propafenone—Vertigo—Doxorubicin—bone cancer	0.000183	0.000792	CcSEcCtD
Propafenone—Anorexia—Methotrexate—bone cancer	0.000183	0.000792	CcSEcCtD
Propafenone—Syncope—Doxorubicin—bone cancer	0.000183	0.00079	CcSEcCtD
Propafenone—Leukopenia—Doxorubicin—bone cancer	0.000182	0.000789	CcSEcCtD
Propafenone—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000182	0.00348	CbGpPWpGaD
Propafenone—Confusional state—Epirubicin—bone cancer	0.000181	0.000784	CcSEcCtD
Propafenone—Palpitations—Doxorubicin—bone cancer	0.00018	0.000779	CcSEcCtD
Propafenone—Oedema—Epirubicin—bone cancer	0.00018	0.000777	CcSEcCtD
Propafenone—Hypotension—Methotrexate—bone cancer	0.00018	0.000776	CcSEcCtD
Propafenone—Loss of consciousness—Doxorubicin—bone cancer	0.000179	0.000774	CcSEcCtD
Propafenone—Infection—Epirubicin—bone cancer	0.000179	0.000772	CcSEcCtD
Propafenone—ADRB1—GPCR ligand binding—GRM4—bone cancer	0.000178	0.00341	CbGpPWpGaD
Propafenone—Cough—Doxorubicin—bone cancer	0.000178	0.000769	CcSEcCtD
Propafenone—Shock—Epirubicin—bone cancer	0.000177	0.000765	CcSEcCtD
Propafenone—Convulsion—Doxorubicin—bone cancer	0.000177	0.000763	CcSEcCtD
Propafenone—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000177	0.00337	CbGpPWpGaD
Propafenone—Nervous system disorder—Epirubicin—bone cancer	0.000176	0.000762	CcSEcCtD
Propafenone—Thrombocytopenia—Epirubicin—bone cancer	0.000176	0.000761	CcSEcCtD
Propafenone—Hypertension—Doxorubicin—bone cancer	0.000176	0.000761	CcSEcCtD
Propafenone—Tachycardia—Epirubicin—bone cancer	0.000176	0.000758	CcSEcCtD
Propafenone—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000175	0.00334	CbGpPWpGaD
Propafenone—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000175	0.000757	CcSEcCtD
Propafenone—Skin disorder—Epirubicin—bone cancer	0.000175	0.000755	CcSEcCtD
Propafenone—Hyperhidrosis—Epirubicin—bone cancer	0.000174	0.000751	CcSEcCtD
Propafenone—Insomnia—Methotrexate—bone cancer	0.000174	0.000751	CcSEcCtD
Propafenone—Chest pain—Doxorubicin—bone cancer	0.000174	0.00075	CcSEcCtD
Propafenone—Myalgia—Doxorubicin—bone cancer	0.000174	0.00075	CcSEcCtD
Propafenone—Anxiety—Doxorubicin—bone cancer	0.000173	0.000747	CcSEcCtD
Propafenone—Paraesthesia—Methotrexate—bone cancer	0.000173	0.000746	CcSEcCtD
Propafenone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000172	0.000745	CcSEcCtD
Propafenone—Discomfort—Doxorubicin—bone cancer	0.000171	0.000741	CcSEcCtD
Propafenone—Anorexia—Epirubicin—bone cancer	0.000171	0.000741	CcSEcCtD
Propafenone—Dyspnoea—Methotrexate—bone cancer	0.000171	0.00074	CcSEcCtD
Propafenone—Somnolence—Methotrexate—bone cancer	0.000171	0.000738	CcSEcCtD
Propafenone—Dry mouth—Doxorubicin—bone cancer	0.00017	0.000734	CcSEcCtD
Propafenone—Dyspepsia—Methotrexate—bone cancer	0.000169	0.000731	CcSEcCtD
Propafenone—Hypotension—Epirubicin—bone cancer	0.000168	0.000726	CcSEcCtD
Propafenone—Confusional state—Doxorubicin—bone cancer	0.000168	0.000725	CcSEcCtD
Propafenone—Decreased appetite—Methotrexate—bone cancer	0.000167	0.000722	CcSEcCtD
Propafenone—Oedema—Doxorubicin—bone cancer	0.000166	0.000719	CcSEcCtD
Propafenone—Gastrointestinal disorder—Methotrexate—bone cancer	0.000166	0.000717	CcSEcCtD
Propafenone—Fatigue—Methotrexate—bone cancer	0.000166	0.000716	CcSEcCtD
Propafenone—Infection—Doxorubicin—bone cancer	0.000165	0.000714	CcSEcCtD
Propafenone—Pain—Methotrexate—bone cancer	0.000164	0.00071	CcSEcCtD
Propafenone—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000164	0.000708	CcSEcCtD
Propafenone—Shock—Doxorubicin—bone cancer	0.000164	0.000707	CcSEcCtD
Propafenone—Nervous system disorder—Doxorubicin—bone cancer	0.000163	0.000705	CcSEcCtD
Propafenone—Thrombocytopenia—Doxorubicin—bone cancer	0.000163	0.000704	CcSEcCtD
Propafenone—Insomnia—Epirubicin—bone cancer	0.000163	0.000703	CcSEcCtD
Propafenone—Tachycardia—Doxorubicin—bone cancer	0.000162	0.000702	CcSEcCtD
Propafenone—Skin disorder—Doxorubicin—bone cancer	0.000162	0.000698	CcSEcCtD
Propafenone—Paraesthesia—Epirubicin—bone cancer	0.000161	0.000698	CcSEcCtD
Propafenone—Hyperhidrosis—Doxorubicin—bone cancer	0.000161	0.000695	CcSEcCtD
Propafenone—Dyspnoea—Epirubicin—bone cancer	0.00016	0.000693	CcSEcCtD
Propafenone—Somnolence—Epirubicin—bone cancer	0.00016	0.000691	CcSEcCtD
Propafenone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000159	0.00303	CbGpPWpGaD
Propafenone—Anorexia—Doxorubicin—bone cancer	0.000159	0.000685	CcSEcCtD
Propafenone—Feeling abnormal—Methotrexate—bone cancer	0.000158	0.000684	CcSEcCtD
Propafenone—Dyspepsia—Epirubicin—bone cancer	0.000158	0.000684	CcSEcCtD
Propafenone—Gastrointestinal pain—Methotrexate—bone cancer	0.000157	0.000679	CcSEcCtD
Propafenone—Decreased appetite—Epirubicin—bone cancer	0.000156	0.000676	CcSEcCtD
Propafenone—Hypotension—Doxorubicin—bone cancer	0.000155	0.000672	CcSEcCtD
Propafenone—Gastrointestinal disorder—Epirubicin—bone cancer	0.000155	0.000671	CcSEcCtD
Propafenone—Fatigue—Epirubicin—bone cancer	0.000155	0.00067	CcSEcCtD
Propafenone—ADRB1—GPCR ligand binding—GRM1—bone cancer	0.000155	0.00295	CbGpPWpGaD
Propafenone—Constipation—Epirubicin—bone cancer	0.000154	0.000665	CcSEcCtD
Propafenone—Pain—Epirubicin—bone cancer	0.000154	0.000665	CcSEcCtD
Propafenone—Urticaria—Methotrexate—bone cancer	0.000153	0.00066	CcSEcCtD
Propafenone—Body temperature increased—Methotrexate—bone cancer	0.000152	0.000656	CcSEcCtD
Propafenone—Abdominal pain—Methotrexate—bone cancer	0.000152	0.000656	CcSEcCtD
Propafenone—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000152	0.000655	CcSEcCtD
Propafenone—SCN5A—L1CAM interactions—EGFR—bone cancer	0.000151	0.00288	CbGpPWpGaD
Propafenone—Insomnia—Doxorubicin—bone cancer	0.00015	0.00065	CcSEcCtD
Propafenone—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00015	0.00286	CbGpPWpGaD
Propafenone—Paraesthesia—Doxorubicin—bone cancer	0.000149	0.000646	CcSEcCtD
Propafenone—Dyspnoea—Doxorubicin—bone cancer	0.000148	0.000641	CcSEcCtD
Propafenone—Feeling abnormal—Epirubicin—bone cancer	0.000148	0.00064	CcSEcCtD
Propafenone—Somnolence—Doxorubicin—bone cancer	0.000148	0.000639	CcSEcCtD
Propafenone—Gastrointestinal pain—Epirubicin—bone cancer	0.000147	0.000635	CcSEcCtD
Propafenone—Dyspepsia—Doxorubicin—bone cancer	0.000146	0.000633	CcSEcCtD
Propafenone—Decreased appetite—Doxorubicin—bone cancer	0.000145	0.000625	CcSEcCtD
Propafenone—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000144	0.000621	CcSEcCtD
Propafenone—Fatigue—Doxorubicin—bone cancer	0.000143	0.00062	CcSEcCtD
Propafenone—Urticaria—Epirubicin—bone cancer	0.000143	0.000617	CcSEcCtD
Propafenone—Pain—Doxorubicin—bone cancer	0.000142	0.000615	CcSEcCtD
Propafenone—Constipation—Doxorubicin—bone cancer	0.000142	0.000615	CcSEcCtD
Propafenone—Body temperature increased—Epirubicin—bone cancer	0.000142	0.000614	CcSEcCtD
Propafenone—Abdominal pain—Epirubicin—bone cancer	0.000142	0.000614	CcSEcCtD
Propafenone—Hypersensitivity—Methotrexate—bone cancer	0.000142	0.000612	CcSEcCtD
Propafenone—Asthenia—Methotrexate—bone cancer	0.000138	0.000596	CcSEcCtD
Propafenone—Feeling abnormal—Doxorubicin—bone cancer	0.000137	0.000593	CcSEcCtD
Propafenone—Gastrointestinal pain—Doxorubicin—bone cancer	0.000136	0.000588	CcSEcCtD
Propafenone—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	0.000136	0.0026	CbGpPWpGaD
Propafenone—Pruritus—Methotrexate—bone cancer	0.000136	0.000587	CcSEcCtD
Propafenone—Hypersensitivity—Epirubicin—bone cancer	0.000132	0.000573	CcSEcCtD
Propafenone—Urticaria—Doxorubicin—bone cancer	0.000132	0.000571	CcSEcCtD
Propafenone—Abdominal pain—Doxorubicin—bone cancer	0.000132	0.000568	CcSEcCtD
Propafenone—Body temperature increased—Doxorubicin—bone cancer	0.000132	0.000568	CcSEcCtD
Propafenone—Diarrhoea—Methotrexate—bone cancer	0.000131	0.000568	CcSEcCtD
Propafenone—SCN5A—SIDS Susceptibility Pathways—JUN—bone cancer	0.00013	0.00249	CbGpPWpGaD
Propafenone—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.00013	0.00248	CbGpPWpGaD
Propafenone—Asthenia—Epirubicin—bone cancer	0.000129	0.000558	CcSEcCtD
Propafenone—Pruritus—Epirubicin—bone cancer	0.000127	0.00055	CcSEcCtD
Propafenone—Dizziness—Methotrexate—bone cancer	0.000127	0.000549	CcSEcCtD
Propafenone—KCNH2—SIDS Susceptibility Pathways—JUN—bone cancer	0.000126	0.00241	CbGpPWpGaD
Propafenone—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000123	0.00235	CbGpPWpGaD
Propafenone—Diarrhoea—Epirubicin—bone cancer	0.000123	0.000532	CcSEcCtD
Propafenone—Hypersensitivity—Doxorubicin—bone cancer	0.000123	0.00053	CcSEcCtD
Propafenone—Vomiting—Methotrexate—bone cancer	0.000122	0.000528	CcSEcCtD
Propafenone—Rash—Methotrexate—bone cancer	0.000121	0.000524	CcSEcCtD
Propafenone—Dermatitis—Methotrexate—bone cancer	0.000121	0.000523	CcSEcCtD
Propafenone—Headache—Methotrexate—bone cancer	0.00012	0.00052	CcSEcCtD
Propafenone—Asthenia—Doxorubicin—bone cancer	0.000119	0.000516	CcSEcCtD
Propafenone—Dizziness—Epirubicin—bone cancer	0.000119	0.000514	CcSEcCtD
Propafenone—Pruritus—Doxorubicin—bone cancer	0.000118	0.000509	CcSEcCtD
Propafenone—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000116	0.00222	CbGpPWpGaD
Propafenone—Vomiting—Epirubicin—bone cancer	0.000114	0.000494	CcSEcCtD
Propafenone—CYP2C8—Biological oxidations—CYP3A4—bone cancer	0.000114	0.00218	CbGpPWpGaD
Propafenone—Nausea—Methotrexate—bone cancer	0.000114	0.000493	CcSEcCtD
Propafenone—Diarrhoea—Doxorubicin—bone cancer	0.000114	0.000492	CcSEcCtD
Propafenone—Rash—Epirubicin—bone cancer	0.000113	0.00049	CcSEcCtD
Propafenone—Dermatitis—Epirubicin—bone cancer	0.000113	0.00049	CcSEcCtD
Propafenone—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	0.000113	0.00215	CbGpPWpGaD
Propafenone—Headache—Epirubicin—bone cancer	0.000113	0.000487	CcSEcCtD
Propafenone—SCN5A—Axon guidance—MET—bone cancer	0.000113	0.00215	CbGpPWpGaD
Propafenone—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000111	0.00211	CbGpPWpGaD
Propafenone—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.00011	0.00211	CbGpPWpGaD
Propafenone—Dizziness—Doxorubicin—bone cancer	0.00011	0.000475	CcSEcCtD
Propafenone—ADRB1—GPCR ligand binding—SMO—bone cancer	0.000109	0.00208	CbGpPWpGaD
Propafenone—KCNH2—Neuronal System—BRAF—bone cancer	0.000109	0.00208	CbGpPWpGaD
Propafenone—Nausea—Epirubicin—bone cancer	0.000107	0.000462	CcSEcCtD
Propafenone—Vomiting—Doxorubicin—bone cancer	0.000106	0.000457	CcSEcCtD
Propafenone—Rash—Doxorubicin—bone cancer	0.000105	0.000453	CcSEcCtD
Propafenone—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000105	0.002	CbGpPWpGaD
Propafenone—Dermatitis—Doxorubicin—bone cancer	0.000105	0.000453	CcSEcCtD
Propafenone—Headache—Doxorubicin—bone cancer	0.000104	0.00045	CcSEcCtD
Propafenone—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000101	0.00193	CbGpPWpGaD
Propafenone—ADRB1—GPCR downstream signaling—GRM4—bone cancer	0.000101	0.00192	CbGpPWpGaD
Propafenone—ADRB1—GPCR downstream signaling—RGS1—bone cancer	0.000101	0.00192	CbGpPWpGaD
Propafenone—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000101	0.00192	CbGpPWpGaD
Propafenone—Nausea—Doxorubicin—bone cancer	9.88e-05	0.000427	CcSEcCtD
Propafenone—CYP2C8—Biological oxidations—GSTP1—bone cancer	9.77e-05	0.00187	CbGpPWpGaD
Propafenone—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	9.64e-05	0.00184	CbGpPWpGaD
Propafenone—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	9.46e-05	0.00181	CbGpPWpGaD
Propafenone—SCN5A—Axon guidance—MMP2—bone cancer	9.39e-05	0.00179	CbGpPWpGaD
Propafenone—CYP2D6—Biological oxidations—CYP3A4—bone cancer	9.38e-05	0.00179	CbGpPWpGaD
Propafenone—CYP2C9—Biological oxidations—CYP3A4—bone cancer	9.3e-05	0.00178	CbGpPWpGaD
Propafenone—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	9.25e-05	0.00177	CbGpPWpGaD
Propafenone—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	9.17e-05	0.00175	CbGpPWpGaD
Propafenone—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	9.15e-05	0.00175	CbGpPWpGaD
Propafenone—ADRB1—Signaling by GPCR—GRM4—bone cancer	9.15e-05	0.00175	CbGpPWpGaD
Propafenone—ADRB1—Signaling by GPCR—RGS1—bone cancer	9.15e-05	0.00175	CbGpPWpGaD
Propafenone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	9.12e-05	0.00174	CbGpPWpGaD
Propafenone—KCNH2—Neuronal System—MDM2—bone cancer	9.11e-05	0.00174	CbGpPWpGaD
Propafenone—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	9.03e-05	0.00172	CbGpPWpGaD
Propafenone—ADRB1—GPCR downstream signaling—GRM1—bone cancer	8.74e-05	0.00167	CbGpPWpGaD
Propafenone—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	8.56e-05	0.00163	CbGpPWpGaD
Propafenone—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	8.1e-05	0.00155	CbGpPWpGaD
Propafenone—SCN5A—Developmental Biology—CDK4—bone cancer	8.03e-05	0.00153	CbGpPWpGaD
Propafenone—SCN5A—Developmental Biology—MET—bone cancer	8.03e-05	0.00153	CbGpPWpGaD
Propafenone—CYP2D6—Biological oxidations—GSTP1—bone cancer	8.02e-05	0.00153	CbGpPWpGaD
Propafenone—CYP2C9—Biological oxidations—GSTP1—bone cancer	7.95e-05	0.00152	CbGpPWpGaD
Propafenone—CYP1A2—Biological oxidations—CYP3A4—bone cancer	7.95e-05	0.00152	CbGpPWpGaD
Propafenone—ADRB1—Signaling by GPCR—GRM1—bone cancer	7.93e-05	0.00152	CbGpPWpGaD
Propafenone—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	7.91e-05	0.00151	CbGpPWpGaD
Propafenone—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	7.84e-05	0.0015	CbGpPWpGaD
Propafenone—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	7.84e-05	0.0015	CbGpPWpGaD
Propafenone—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	7.65e-05	0.00146	CbGpPWpGaD
Propafenone—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	7.63e-05	0.00146	CbGpPWpGaD
Propafenone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	7.17e-05	0.00137	CbGpPWpGaD
Propafenone—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	7.17e-05	0.00137	CbGpPWpGaD
Propafenone—SCN5A—Axon guidance—MMP9—bone cancer	7.05e-05	0.00135	CbGpPWpGaD
Propafenone—CYP2C8—Metabolism—NDUFA12—bone cancer	6.85e-05	0.00131	CbGpPWpGaD
Propafenone—CYP1A2—Biological oxidations—GSTP1—bone cancer	6.8e-05	0.0013	CbGpPWpGaD
Propafenone—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	6.7e-05	0.00128	CbGpPWpGaD
Propafenone—SCN5A—Developmental Biology—MMP2—bone cancer	6.7e-05	0.00128	CbGpPWpGaD
Propafenone—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	6.59e-05	0.00126	CbGpPWpGaD
Propafenone—ABCB1—Metabolism—NDUFA12—bone cancer	5.97e-05	0.00114	CbGpPWpGaD
Propafenone—SCN5A—Axon guidance—EGFR—bone cancer	5.7e-05	0.00109	CbGpPWpGaD
Propafenone—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	5.68e-05	0.00108	CbGpPWpGaD
Propafenone—CYP2C8—Metabolism—NT5C3A—bone cancer	5.68e-05	0.00108	CbGpPWpGaD
Propafenone—ADRB1—GPCR downstream signaling—GNA11—bone cancer	5.63e-05	0.00108	CbGpPWpGaD
Propafenone—CYP2D6—Metabolism—NDUFA12—bone cancer	5.62e-05	0.00107	CbGpPWpGaD
Propafenone—ADRB1—Signaling by GPCR—SMO—bone cancer	5.59e-05	0.00107	CbGpPWpGaD
Propafenone—CYP2C9—Metabolism—NDUFA12—bone cancer	5.57e-05	0.00106	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—GRM4—bone cancer	5.41e-05	0.00103	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—RGS1—bone cancer	5.41e-05	0.00103	CbGpPWpGaD
Propafenone—CYP3A4—Biological oxidations—GSTP1—bone cancer	5.25e-05	0.001	CbGpPWpGaD
Propafenone—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	5.17e-05	0.000988	CbGpPWpGaD
Propafenone—ADRB1—Signaling by GPCR—GNA11—bone cancer	5.11e-05	0.000977	CbGpPWpGaD
Propafenone—ADRB1—GPCR downstream signaling—IL3—bone cancer	5.1e-05	0.000975	CbGpPWpGaD
Propafenone—SCN5A—Developmental Biology—MMP9—bone cancer	5.03e-05	0.000962	CbGpPWpGaD
Propafenone—ABCB1—Metabolism—NT5C3A—bone cancer	4.94e-05	0.000944	CbGpPWpGaD
Propafenone—CYP1A2—Metabolism—NDUFA12—bone cancer	4.76e-05	0.00091	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—GRM1—bone cancer	4.69e-05	0.000895	CbGpPWpGaD
Propafenone—CYP2D6—Metabolism—NT5C3A—bone cancer	4.66e-05	0.00089	CbGpPWpGaD
Propafenone—ADRB1—Signaling by GPCR—IL3—bone cancer	4.64e-05	0.000885	CbGpPWpGaD
Propafenone—CYP2C9—Metabolism—NT5C3A—bone cancer	4.62e-05	0.000882	CbGpPWpGaD
Propafenone—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	4.21e-05	0.000804	CbGpPWpGaD
Propafenone—SCN5A—Developmental Biology—EGFR—bone cancer	4.07e-05	0.000777	CbGpPWpGaD
Propafenone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	4.06e-05	0.000775	CbGpPWpGaD
Propafenone—CYP1A2—Metabolism—NT5C3A—bone cancer	3.95e-05	0.000754	CbGpPWpGaD
Propafenone—CYP3A4—Metabolism—NDUFA12—bone cancer	3.68e-05	0.000702	CbGpPWpGaD
Propafenone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	3.66e-05	0.000699	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—SMO—bone cancer	3.3e-05	0.000631	CbGpPWpGaD
Propafenone—CYP3A4—Metabolism—NT5C3A—bone cancer	3.05e-05	0.000582	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—GNA11—bone cancer	3.02e-05	0.000577	CbGpPWpGaD
Propafenone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.88e-05	0.000549	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—ATF1—bone cancer	2.81e-05	0.000536	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—IL3—bone cancer	2.74e-05	0.000523	CbGpPWpGaD
Propafenone—CYP2C8—Metabolism—ENO2—bone cancer	2.49e-05	0.000475	CbGpPWpGaD
Propafenone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.41e-05	0.000461	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—TGFBR2—bone cancer	2.34e-05	0.000447	CbGpPWpGaD
Propafenone—CYP2C8—Metabolism—DHFR—bone cancer	2.31e-05	0.00044	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—IGF1R—bone cancer	2.2e-05	0.000421	CbGpPWpGaD
Propafenone—ABCB1—Metabolism—ENO2—bone cancer	2.17e-05	0.000414	CbGpPWpGaD
Propafenone—CYP2C8—Metabolism—GNA11—bone cancer	2.16e-05	0.000412	CbGpPWpGaD
Propafenone—CYP2D6—Metabolism—ENO2—bone cancer	2.04e-05	0.00039	CbGpPWpGaD
Propafenone—CYP2C9—Metabolism—ENO2—bone cancer	2.02e-05	0.000386	CbGpPWpGaD
Propafenone—ABCB1—Metabolism—DHFR—bone cancer	2.01e-05	0.000384	CbGpPWpGaD
Propafenone—CYP2C8—Metabolism—CYP3A4—bone cancer	1.95e-05	0.000373	CbGpPWpGaD
Propafenone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.94e-05	0.000371	CbGpPWpGaD
Propafenone—CYP2D6—Metabolism—DHFR—bone cancer	1.89e-05	0.000362	CbGpPWpGaD
Propafenone—ABCB1—Metabolism—GNA11—bone cancer	1.88e-05	0.000359	CbGpPWpGaD
Propafenone—CYP2C9—Metabolism—DHFR—bone cancer	1.88e-05	0.000359	CbGpPWpGaD
Propafenone—CYP2D6—Metabolism—GNA11—bone cancer	1.77e-05	0.000338	CbGpPWpGaD
Propafenone—CYP2C9—Metabolism—GNA11—bone cancer	1.75e-05	0.000335	CbGpPWpGaD
Propafenone—CYP1A2—Metabolism—ENO2—bone cancer	1.73e-05	0.00033	CbGpPWpGaD
Propafenone—ABCB1—Metabolism—CYP3A4—bone cancer	1.7e-05	0.000325	CbGpPWpGaD
Propafenone—CYP2C8—Metabolism—GSTP1—bone cancer	1.67e-05	0.000319	CbGpPWpGaD
Propafenone—CYP2D6—Metabolism—CYP3A4—bone cancer	1.6e-05	0.000306	CbGpPWpGaD
Propafenone—CYP1A2—Metabolism—DHFR—bone cancer	1.6e-05	0.000306	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—KIT—bone cancer	1.6e-05	0.000305	CbGpPWpGaD
Propafenone—CYP2C9—Metabolism—CYP3A4—bone cancer	1.59e-05	0.000304	CbGpPWpGaD
Propafenone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.58e-05	0.000302	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—BRAF—bone cancer	1.5e-05	0.000287	CbGpPWpGaD
Propafenone—CYP1A2—Metabolism—GNA11—bone cancer	1.5e-05	0.000286	CbGpPWpGaD
Propafenone—ABCB1—Metabolism—GSTP1—bone cancer	1.46e-05	0.000278	CbGpPWpGaD
Propafenone—ADRB1—Signaling by GPCR—EGFR—bone cancer	1.46e-05	0.000278	CbGpPWpGaD
Propafenone—CYP2D6—Metabolism—GSTP1—bone cancer	1.37e-05	0.000262	CbGpPWpGaD
Propafenone—CYP2C9—Metabolism—GSTP1—bone cancer	1.36e-05	0.00026	CbGpPWpGaD
Propafenone—CYP1A2—Metabolism—CYP3A4—bone cancer	1.36e-05	0.00026	CbGpPWpGaD
Propafenone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.35e-05	0.000258	CbGpPWpGaD
Propafenone—CYP3A4—Metabolism—ENO2—bone cancer	1.33e-05	0.000255	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—MDM2—bone cancer	1.26e-05	0.00024	CbGpPWpGaD
Propafenone—CYP3A4—Metabolism—DHFR—bone cancer	1.24e-05	0.000236	CbGpPWpGaD
Propafenone—CYP1A2—Metabolism—GSTP1—bone cancer	1.16e-05	0.000222	CbGpPWpGaD
Propafenone—CYP3A4—Metabolism—GNA11—bone cancer	1.16e-05	0.000221	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—JUN—bone cancer	1.09e-05	0.000209	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—MMP9—bone cancer	1.06e-05	0.000203	CbGpPWpGaD
Propafenone—CYP3A4—Metabolism—GSTP1—bone cancer	8.97e-06	0.000171	CbGpPWpGaD
Propafenone—CYP2C8—Metabolism—PTGS2—bone cancer	8.66e-06	0.000165	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—EGFR—bone cancer	8.6e-06	0.000164	CbGpPWpGaD
Propafenone—ABCB1—Metabolism—PTGS2—bone cancer	7.54e-06	0.000144	CbGpPWpGaD
Propafenone—ADRB1—Signaling Pathways—TP53—bone cancer	7.22e-06	0.000138	CbGpPWpGaD
Propafenone—CYP2D6—Metabolism—PTGS2—bone cancer	7.11e-06	0.000136	CbGpPWpGaD
Propafenone—CYP2C9—Metabolism—PTGS2—bone cancer	7.05e-06	0.000135	CbGpPWpGaD
Propafenone—CYP1A2—Metabolism—PTGS2—bone cancer	6.02e-06	0.000115	CbGpPWpGaD
Propafenone—CYP3A4—Metabolism—PTGS2—bone cancer	4.65e-06	8.88e-05	CbGpPWpGaD
